Isomerase Therapeutics aquires assets from Biotica Technology


Isomerase Therapeutics Ltd., the biosynthetic engineering drug discovery company announces that it has acquired assets from Biotica Technology Ltd. and is seeking collaborations to employ its microbial natural product optimization technology. 


March 15, 2013--Cambridge


Isomerase Therapeutics announces that it has acquired compounds, strains and intellectual property from Biotica Technology Ltd. This acquisiton was carried out under the administration process at Biotica, and was completed by the joint administrators, Chris McKay and Andrew McTear at McTear, Williams and Wood.


Dr Matt Gregory, CEO of Isomerase commented "Our acquisition makes Isomerase Therapeutics a major player in the bioengineering field, with a real opportunity to engage in drug discovery and development collaborations and offer a robust and rapid route to optimising a class of drugs with outstanding biology, but difficult chemistry."



Isomerase Therapeutics is a drug discovery biotech company based in Cambridge, UK. It offers drug discovery and development services for companies looking to develop microbial natural products into drugs, using its unique bioengineering services supported by a portfolio of technology IP and the combined experience of a core scientific team from over a decade of successful drug discovery and development collaborations with Pharma and Biotech.

For further information, please contact Dr Matt Gregory via our contact page.

Cookies user preferences
All essential cookies are mandatory in order to allow logging in and submitting forms etc. You can choose to decline some non-essential ones.
Accept all
Decline all
Read more
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.